Analytical Data
-
Gene name
TCEAL5
- Application
-
Alternative Names
TCEAL5; Transcription elongation factor A Protein-like 5; TCEA-like Protein 5; Transcription elongation factor S-II Protein-like 5
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5H9L2
-
Expression Region
1-206 aa
-
AA Sequence
MEKLYKENEG KPENERNLES EGKPEDEGST EDEGKSDEEE KPDMEGKTEC EGKREDEGEP GDEGQLEDEG NQEKQGKSEG EDKPQSEGKP ASQAKPESQP RAAEKRPAED YVPRKAKRKT DRGTDDSPKD SQEDLQERHL SSEEMMRECG DVSRAQEELR KKQKMGGFHW MQRDVQDPFA PRGQRGVRGV RGGGRGQKDL EDVPYV
-
Molecular Weight
23.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TCEAL5, or T-cell expressed sequence 5, is a member of the TCEAL protein family, which has garnered attention due to its potential involvement in various cellular processes, including transcriptional regulation and immune response. Research on TCEAL5 has indicated its expression in T-cells and other immune-related tissues, suggesting a role in the modulation of immune functions. Studies have previously linked TCEAL proteins to oncogenic processes and disease states, making TCEAL5 a candidate for further investigation in cancer research and immunology. The characterization of TCEAL5 as a recombinant protein serves multiple purposes, including understanding its structure-function relationships, elucidating its role in T-cell signaling pathways, and its potential as a therapeutic target. Recombinant protein technology allows for the production of TCEAL5 in significant quantities, enabling detailed biochemical and biophysical studies. By examining its interactions with other cellular proteins and its impact on gene expression, researchers aim to establish a clearer understanding of how TCEAL5 influences immune responses and contributes to pathophysiological conditions such as cancer and autoimmune diseases. The findings derived from these studies could pave the way for novel therapeutic strategies leveraging TCEAL5's function in immune regulation and cancer biology. Overall, TCEAL5 represents a promising avenue for research that could lead to significant advancements in immunotherapy and targeted cancer treatments.
